International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study

Figures

• 

  Figure 1. Age distribution for 1006 of the 1008 cats with obstructive and nonobstructive hypertrophic cardiomyopathy recorded at the time of diagnosis. In 2 cats, age was not recorded

• 

  Figure 2. Most prevalent breeds in feline study populations. HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy

• 

  Figure 3. Kaplan‐Meier survival curves estimating percentage of 430 cats with nonobstructive (HCM) compared with 578 cats with the obstructive (HOCM) form of hypertrophic cardiomyopathy that have not yet experienced morbidity (Y‐axis) from CHF (top) or ATE (bottom) against time (X‐axis)

• 

  Figure 4. Percentage of 1008 cats with nonobstructive (HCM, n = 430) and obstructive (HOCM, n = 578) hypertrophic cardiomyopathy at risk for cardiovascular mortality, by age quartile when diagnosed and assessed 1, 5, and 10 years after study entry. Q, age quartile; yrs., years

• 

  Figure 5. Kaplan‐Meier survival curves estimating percentage of 1008 cats with nonobstructive (HCM, n = 430) and obstructive (HOCM, n = 578) forms of hypertrophic cardiomyopathy that have not yet experienced cardiovascular death (Y‐axis) compared with 722 AH against time (Y‐axis). NA, median not estimable

• 

  Figure 6. Kaplan‐Meier survival curves estimating percentage of 430 cats with nonobstructive (HCM) compared with 578 cats with the obstructive form (HOCM) of hypertrophic cardiomyopathy that have not yet experienced cardiovascular death (Y‐axis) against time (X‐axis). NA, median not estimable

• 

  Figure 7. Kaplan‐Meier survival curves estimating the percentage of 430 cats with nonobstructive (HCM) compared with 578 cats with obstructive (HOCM) hypertrophic cardiomyopathy that have not yet experienced cardiovascular death (Y‐axis) for CHF (A), or ATE (B) against time (X‐axis). NA, median not estimable

• 

  Figure 8. Kaplan‐Meier survival curves estimating the EFS proportion and PES proportion (Y‐axis) against time (X‐axis). Event‐free survival group‐A comprised a cohort of 140 cats with preclinical hypertrophic cardiomyopathy who died on the day of their first recorded CHF/ATE morbidity. Event‐free survival group‐B comprised a cohort of 119 cats with preclinical hypertrophic cardiomyopathy who survived more than one day after their first recorded CHF/ATE morbidity. Postevent survival was calculated for these 119 cats. *P = .101; **P < .0001; SD, standard deviation